Exousia Pro $MAJI Shareholder Update: We are pleased to report a significant legal victory that supports our commitment to maximizing shareholder value. Following the hearing on December 16, 2025, the Court issued a favorable ruling, DENYING the Motion to Dismiss filed by Don

$MAJI Shareholders | Update on our CBD Division: The potential for Medicare reimbursement of CBD-based products could substantially expand the market size and commercial opportunity for our CBD-Exosomes. This comes as we have successfully loaded milk-derived exosomes with CBD, a

Strategic execution is accelerating shareholder value at Exousia Pro $MAJI! The pending acquisition of our new Telehealth Platform provides the immediate channel needed to onboard the targeted 1,000 patients. This critical synergy is projected to generate an additional $50,000

Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization

https://t.co/byeneKUzOn

Exousia Pro - $MAJI - unveils the full spectrum power of Maxasome™! This isn't just a supplement—it's cellular armor delivered by 100% Pure Exosomal Technology. Maxasome™, derived from Yellow Oyster Mushrooms, provides a potent, natural blend of Ergothioneine (EGT),

$MAJI - new supplement Maxasome™ health benefits:

Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement

$LMMY Interview with Dr. Marvin Hausman https://t.co/Jo3TOkY0TL

$MAJI We are launching a premarket IRB approved clinical study, to validate our patented state-of-the-art NANOG DNA cancer screening test.

Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms

$LMMY releases news on it acquisition. https://t.co/opjAym4NsM

Welcome Shareholders to the Official “X” Account for Exousia Bio Inc. ( $LMMY ) - In just a few days, we will begin to release our first major update, formally kicking off what we believe will be a transformative and thrilling journey for the company.

All $MAJI followers should follow @ExousiaBio

$MAJI will soon announce multiple exciting acquisitions within our Exousia Health division. We are having all the target companies audited, to ensure a smooth integration and to position them for inclusion in our future S-1 registration. This is just the beginning—much more is on

Strategic Control Secured! $MAJI will receive Super Voting Preferred stock in LMMY, giving us the essential leverage to both safeguard our investment and meticulously manage the future use of our core IP and licensing agreement. This important equity piece ensures we maintain

Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value

$MAJI BREAKTHROUGH A NEW PATENT SECURED! We now control two revolutionary areas: a patented exosome-based cancer treatment AND a patented screening test capable of detecting cancer when it's just a few cells, before a tumor even forms. We believe this will become the new standard

$MAJI is looking forward to answering any and all of your questions. We believe we can help settle any nerves and clear up any confusion.

https://t.co/SdJTpPP5ik